Eligard 3 Month TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: inert substance, leuprorelin
Pack: Eligard 3 Month (1 x 22.5 mg syringe, 1 x inert diluent syringe), 1 pack
Brand name
(ARTG)
: ELIGARD leuprorelin acetate 22.5mg modified release injection syringeDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Prostate cancer,ELIGARD 7.5mg 1 month, ELIGARD 22.5mg 3 month, ELIGARD 30mg 4 month and ELIGARD 45mg 6 month are indicated for the:, Palliative treatment of advanced prostate cancer., Treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.
How to use this medicine
(ARTG)
This medicine is a pack that contains more than one component.
Component :
- Injection, modified release
- Subcutaneous
- A white to off-white powder. Substantially free of foreign matter with no evidence of meltback.
Component :
- Injection, modified release
- Subcutaneous
- Colourless to pale yellow clear viscous solution. May contain air bubbles but if free from visible particles and foreign matter.
Storage conditions
(ARTG)
- Store below 8 degrees Celsius (refrigerate)
- Refrigerate
- Shelf lifetime is 2 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 injection, containing syringe A & syringe B. pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient leuprorelin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
